The current financial score of NanoViricides Inc is 5.52. Its financial status is weak, and its operating efficiency is low.
The current valuation score of NanoViricides Inc is 6.01. Its current P/E ratio is -3.48, which is -63.01% below the recent high of -1.29 and -23.18% above the recent low of -4.28.
The current earnings forecast score of NanoViricides Inc is 8.00. The average price target is 6.00, with a high of 6.00 and a low of 6.00.
The current price momentum score of NanoViricides Inc is 6.27. Currently, the stock price is trading between the resistance level at 1.86 and the support level at 1.08, making it suitable for range-bound swing trading.
The current institutional shareholding score of NanoViricides Inc is 3.00. The latest institutional shareholding proportion is 18.22%, representing a quarter-over-quarter increase of 173.22%. The largest institutional shareholder is James Simons, holding a total of 128.60K shares, representing 0.00% of shares outstanding, with 30.48% increase in holdings.
No risk assessment score is currently available for NanoViricides Inc. The Biotechnology & Medical Research industry's average is 3.94. The company's beta value is 1.66. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.